Positive News SentimentPositive NewsNASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $6.40 -0.15 (-2.29%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$6.40 0.00 (0.00%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EPRX alerts:Sign Up Key Stats Today's Range$6.15▼$6.7450-Day Range$5.81▼$7.5352-Week Range$5.04▼$9.32Volume457,159 shsAverage Volume346,647 shsMarket Capitalization$416.13 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus. Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach. Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.AI Generated. May Contain Errors. Read More Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreEPRX MarketRank™: Eupraxia Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 471st out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEupraxia Pharmaceuticals has a consensus price target of $18.00, representing about 181.3% upside from its current price of $6.40.Amount of Analyst CoverageEupraxia Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.88) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eupraxia Pharmaceuticals is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eupraxia Pharmaceuticals is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEupraxia Pharmaceuticals has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.11% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 25.74, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently increased by 8.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.77 News SentimentEupraxia Pharmaceuticals has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsEupraxia Pharmaceuticals has minimal institutional ownership at this time.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Stock News HeadlinesCantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)July 22, 2026 | theglobeandmail.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthJuly 14, 2026 | finanznachrichten.deYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire. | SmartAsset (Ad)Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthJuly 13, 2026 | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and CommercializationJuly 9, 2026 | finanznachrichten.deEupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline AdvancesJuly 7, 2026 | tipranks.comEupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and CommercializationJuly 7, 2026 | globenewswire.comEupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGMJune 22, 2026 | tipranks.comSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $7.55 on January 1st, 2026. Since then, EPRX shares have decreased by 15.2% and is now trading at $6.40. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eupraxia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY). Company Calendar Last Earnings5/12/2026Today8/01/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 2 weeks, EPRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees29Year Founded2012Price Target and Rating Average Price Target for Eupraxia Pharmaceuticals$18.00 High Price Target$25.00 Low Price Target$11.00 Potential Upside/Downside+181.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.56% Return on Assets-51.20% Debt Debt-to-Equity Ratio0.02 Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book4.54Miscellaneous Outstanding Shares65,020,000Free FloatN/AMarket Cap$416.13 million OptionableN/A Beta1.05 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:EPRX) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredAmerica Is Following in Greece's FootstepsItaly in the 90s. Argentina in 2001. Greece in 2009. America was always safe… But now the IMF is projecting th...Decentralized Masters | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
